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Summary
Background Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from 
clinical trials are inconsistent and the population in which most beneﬁ t is derived is uncertain. Our aim was to assess 
the addition of panitumumab to irinotecan in pretreated advanced colorectal cancer. 
Methods In this open-label, randomised trial, we enrolled patients who had advanced colorectal cancer progressing after 
ﬂ uoropyrimidine treatment with or without oxaliplatin from 60 centres in the UK. From December, 2006 until June, 
2008, molecularly unselected patients were recruited to a three-arm design including irinotecan (control), irinotecan plus 
ciclosporin, and irinotecan plus panitumumab (IrPan) groups. From June 10, 2008, in response to new data, the trial was 
amended to a prospectively stratiﬁ ed design, restricting panitumumab randomisation to patients with KRAS wild-type 
tumours; the results of the comparison between the irinotcan and IrPan groups are reported here. We used a computer-
generated randomisation sequence (stratiﬁ ed by previous EGFR targeted therapy and then minimised by centre, WHO 
performance status, previous oxaliplatin, previous bevacizumab, previous dose modiﬁ cations, and best previous 
response) to randomly allocate patients to either irinotecan or IrPan. Patients in both groups received 350 mg/m² 
intravenous irinotecan every 3 weeks (300 mg/m² if aged ≥70 years or a performance status of 2); patients in the IrPan 
group also received intravenous panitumumab 9 mg/kg every 3 weeks. The primary endpoint was overall survival in 
KRAS wild-type patients who had not received previous EGFR targeted therapy, analysed by intention to treat. Tumour 
DNA was pyrosequenced for KRASc.146, BRAF, NRAS, and PIK3CA mutations, and predeﬁ ned molecular subgroups were 
analysed for interaction with the eﬀ ect of panitumumab. This study is registered, number ISRCTN93248876.
Results Between Dec 4, 2006, and Aug 31, 2010, 1198 patients were enrolled, of whom 460 were included in the 
primary population of patients with KRASc.12–13,61 wild-type tumours and no previous EGFR targeted therapy. 
230 patients were randomly allocated to irinotecan and 230 to IrPan. There was no diﬀ erence in overall survival 
between groups (HR 1·01, 95% CI 0·83–1·23; p=0·91), but individuals in the IrPan group had longer progression-
free survival (0·78, 0·64–0·95; p=0·015) and a greater number of responses (79 [34%] patients vs 27 [12%]; p<0·0001) 
than did individuals in the irinotecan group. Grade 3 or worse diarrhoea (64 [29%] of 219 patients vs 39 [18%] of 218 
patients), skin toxicity (41 [19%] vs none), lethargy (45 [21]% vs 24 [11%]), infection (42 [19%] vs 22 [10%]) and 
haematological toxicity (48 [22%] vs 27 [12%]) were reported more commonly in the IrPan group than in the irinotecan 
group. We recorded ﬁ ve treatment-related deaths, two in the IrPan group and three in the irinotecan group.
Interpretation Adding panitumumab to irinotecan did not improve the overall survival of patients with wild-type 
KRAS tumours. Further reﬁ nement of molecular selection is needed for substantial beneﬁ ts to be derived from EGFR 
targeting agents. 
Funding Cancer Research UK, Amgen Inc.
Introduction
In 2003, therapeutic antibodies targeting EGFR entered 
phase 3 trials in advanced colorectal cancer. In December, 
2006, the UK Colorectal Clinical Studies Group launched 
a randomised trial in ﬂ uorouracil-resistant advanced 
colorectal cancer, called the Panitumumab, Irinotecan, 
and Ciclosporin in COLOrectal cancer (PICCOLO) trial. 
We selected patients using conventional clinico patho-
logical criteria and allocated them randomly in equal 
distributions to one of three groups: irinotecan alone, 
irinotecan plus ciclosporin, or irinotecan plus 
panitumumab (IrPan). 
In April, 2008, KRAS mutation was reported to be a 
negative predictive biomarker for EGFR targeted 
therapy—retrospective analysis of a randomised trial1 of 
panitumumab versus supportive care showed that 
panitumumab beneﬁ t was conﬁ ned to patients with 
tumours wild-type at KRAS codons 12–13 (p<0·0001). 
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230 allocated to irinotecan
         223 received allocated intervention
              7 did not receive allocated intervention
230 allocated to  IrPan
         224 received allocated intervention
              6 did not receive allocated intervention
230 analysed (intention to treat; 5 withdrew 
from follow-up)
 220 discontinued intervention
  12 toxicity
  21 patient choice
  122 progression
  34 patient died
  31 other or unknown reason
 10 still on treatment
223 in safety population (7 excluded from 
  safety population)
230 analysed (intention to treat; 4 withdrew 
from follow-up)
 207 discontinued intervention
  20 toxicity
  10 patient choice
  110 progression
  36 patient died
  31 other/unknown reason
 23 still on treatment
224 in safety population (6 excluded from 
  safety population
314 KRASc.12,13,61-wt, no previous EGFR-mAb 
         (157 irinotecan, 157 IrPan)
146 KRASc.12,13,61-wt, no previous EGFR-mAb 
         (73 irinotecan, 73 IrPan)
460 in the primary analysis population
         (KRASc.12,13,61-wt, no previous EGFR-mAb)
200 received irinotecan200 received IrCs 177 received irinotecan172 received IrPan 135 received irinotecan177 received IrPan 137 received IrCs
40 KRASc.12,13,61-wt, previous EGFR-mAb 
         (20 irinotecan, 20 IrPan)
52 KRASc.12,13,61 status undetermined, no 
      previous EGFR-mAb (24 irinotecan, 28 IrPan) 
11 KRASc.12,13,61 status undetermined, previous 
      EGFR-mAb (6 irinotecan, 5 IrPan) 
   7 KRASc.12,13,61-mut, previous EGFR-mAb 
      (2 irinotecan, 5 IrPan)
103 KRASc.12,13,61-mut, previous EGFR-mAb 
         (53 irinotecan, 50 IrPan)
23 KRASc.12,13,61-wt, previous EGFR-mAb 
         (12 irinotecan, 11 IrPan)
354 KRASc.12,13,61-wt 272 KRASc.12,13,61-mut/ unknown  
Dec 2006–Aug 2008 
572 included in three-arm trial* 
Sep 2008–Aug 2010 
626 included in the stratified trial 
758 patients excluded 
         415 did not meet inclusion criteria
         186 declined to participate
            21 too ill to consent 
          136 other reasons
1956 patients assessed for eligibility
1198 randomly allocated
Figure 1: Trial proﬁ le
*Between June, 2008, and August, 2008, a temporary safety measure was implemented to exclude patients with unknown or mutated KRASc.12,13,61 status from randomisation to IrPan. 78 patients 
randomised during this period. 30 patients were randomised to irinotecan under the irinotecan vs IrCs comparison only during this time, and are not included in the summaries of patients forming the 
irinotecan vs IrPan comparison. IrCs=irinotecan plus ciclosporin. IrPan=irinotecan plus panitumumab. mAb=monoclonal antibody.
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Two months later, retrospective analysis of two further 
randomised trials2,3 showed similar results for cetuximab. 
By that time, we had recruited 494 of the planned 1269 
patients to PICCOLO. The Trial Management Group 
(including patients representatives) and an independent 
data monitoring and ethics committee agreed that 
continued randomisation of patients with KRAS 
mutations to panitumumab would not be beneﬁ cial to the 
patients nor would it provide useful data. The aim of the 
trial was therefore amended: evaluation of panitumumab 
would now focus on patients with KRAS wild-type 
tumours, with quantiﬁ cation of treatment beneﬁ t and 
evaluation of further biomarkers in this selected 
population, rather than in an unselected population. On 
June 10, 2008, 1 week after announcement of the 
cetuximab data, a safety amendment was introduced to 
exclude patients with KRAS-mutated tumours from 
randomisation to the IrPan group; within 3 months 
PICCOLO was reopened as a prospectively stratiﬁ ed trial: 
patients with KRAS wild-type tumours were randomly 
allocated to irinotecan or IrPan while those with KRAS 
mutations (or unknown KRAS status) were randomly 
allocated to irinotecan or irinotecan plus ciclosporin. We 
present here the ﬁ nal results of the irinotecan versus 
IrPan comparison for patients with KRAS wild-type 
tumours who had not received previous anti-EGFR 
therapy; ﬁ ndings from the irinotecan versus irinotecan 
plus ciclosporin comparison will be reported elsewhere.4
Methods
Study design and patients
PICCOLO was a multicentre, randomised controlled trial 
in chemoresistant advanced colorectal cancer. Recruit-
ment of molecularly unselected patients started on Dec 4, 
2006; panitumumab randomisation was restricted to 
known KRAS-wild type patients from June 10, 2008; it 
was then relaunched with full prospective molecular 
stratiﬁ cation from Aug 31, 2008, and closed to 
recruitment on Aug 31, 2010. 
We recruited patients from 60 centres in the UK. 
Eligible patients were aged 18 years or older, had 
histologically conﬁ rmed colorectal cancer, inoperable 
advanced disease, and had progressed during or after 
ﬂ uoro pyrimidine-containing chemotherapy. Patients 
could have received any previous drugs except for 
irinotecan. Other eligibility criteria were as follows: 
Response Evaluation Criteria In Solid Tumors (RECIST) 
measurable disease;5 WHO per for mance status 0–2; 
haemoglobin concentration of 100 g/L or greater; white 
blood cell count of greater than or equal to 3·0 × 10⁹ cells 
per L; a platelet count of greater than or equal to 100 × 10⁹ 
per L; estimated glomerular ﬁ ltration rate of greater than 
or equal to 50 mL min–¹; bilirubin concentration less 
than or equal to 25 μmol/L; and alkaline phosphatase 
concentrations of ﬁ ve times the upper limit of normal or 
lower and aminotransferase concentrations of 2·5 times 
upper limit of normal or lower. 
Nationwide ethical approval was obtained. Before 
enrolment, patients provided written consent to 
participate, and for the molecular studies.
Randomisation and masking
From Dec 4, 2006, to June 9, 2008, patients were allocated 
equally to irinotecan alone, irinotecan plus ciclosporin, 
or IrPan. Randomisation was done with an automated 
telephonic system at the Clinical Trials Research Unit, 
University of Leeds, UK, using a computer-generated 
minimisation algorithm including a random element, 
ﬁ rst stratiﬁ ed by previous treatment with EGFR 
monoclonal antibodies, then minimised within each of 
the following strata: centre, WHO performance status, 
previous oxaliplatin, previous bevacizumab, previous 
dose modiﬁ cations, and best previous response. 
On June 10, 2008, a temporary safety measure was 
applied that restricted the allocation of patients with 
unknown or mutated KRAS status to the irinotecan or 
irinotecan plus ciclosporin groups only. Regulatory and 
ethical approval of a fully amended, molecularly stratiﬁ ed 
protocol was obtained on Aug 4, 2008. Under the new 
protocol, patients were pre-registered (either when 
PICCOLO therapy was indicated or pre-emptively during 
ﬁ rst-line therapy) and stored resection or biopsy tumour 
material was retrieved and tested for KRASc.12,13,61. To reduce 
the possibility of patients in the control group (irinotecan 
only) being discontinued from treatment prematurely, and 
after consultation with the patient representative on the 
Trial Management Group, patients and their clinicians 
were not routinely made aware of patients’ KRAS status, 
but the information was available on request. Random-
isation occurred immediately before starting treatment.
In the amended protocol, randomisation was stratiﬁ ed 
by KRAS status: patients with KRAS wild-type tumours 
were randomised in a one-to-one ratio to irinotecan or 
IrPan. If KRAS was mutated or unknown, randomisation 
was one-to-one to irinotecan or irinotecan plus ciclosporin. 
24
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Figure 2: Molecular characterisation
IrPan=irinotecan plus panitumumab. mAb=monclonal antibody.
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Randomisation in each comparison was via mini-
misation, incorporating a random element adjusting for 
the same minimisation factors under the original 
protocol. In the irinotecan versus IrPan comparison, 
patients were ﬁ rst stratiﬁ ed by previous EGFR targeted 
therapy, with minimisation done separately within each 
stratum. This was an open-label trial, so patients and 
clinicians were not masked to treatment allocation.
Procedures
The full protocol is available online. Brieﬂ y, all patients 
received an intravenous infusion of irinotecan 350 mg/m² 
every 3 weeks (300 mg/m² if aged >70 years or if they had 
a performance status of 2); patients in the IrPan group 
also received an intravenous infusion of panitumumab 
9 mg/kg every 3 weeks (a schedule based on previous 
pharmacokinetic and pharmacodynamic data6). We 
followed detailed schemes for the management of toxicity, 
including treatment delays and dose reductions (full 
details given in the protocol). Brieﬂ y, a 1-week delay was 
given for unresolved non-haematological toxicities of 
grade 2 or higher; patients who had toxicities of grade 3 or 
higher, or a toxicity requiring two dose delays, had a 20% 
dose reduction. Treatment continued until disease 
progression or unacceptable toxicity. After 12 weeks (four 
cycles) patients with stable or responding disease could, at 
the clinicians’ discretion, be oﬀ ered a planned break from 
irinotecan of up to two cycles; patients on IrPan continued 
panitumumab alone during irinotecan breaks. There was 
no within-protocol crossover, but post-trial treatment was 
not restricted.
RECIST5 response was assessed every 12 weeks with 
CT scans, scored locally, and quality-assured by central 
review in more than a third of patients. Toxicity was 
scored using NCI Common Terminology Criteria for 
Adverse Events (version 3.0). Quality of life was assessed 
at baseline, week 12, and week 24 with EORTC QLQ-C30,7 
EQ-5D,8 and Dermatology Life Quality Index.9
Laboratory methods are described in the appendix and 
elsewhere.10 Quality assured DNA pyrosequencing was 
done at the Cancer Research UK Genomics Facility, 
Irinotecan group 
(n=230)
IrPan group 
(n=230)
Sex
Male 158 (69%) 160 (70%)
Female 72 (31%) 70 (30%)
Age (years) 63 (56–69) 64 (57–70)
WHO performance status
0–1 217 (94%) 217 (94%)
2 13 (6%) 13 (6%)
Primary tumour resected
Yes 179 (78%) 159 (69%)
No 51 (22%) 71 (31%)
Previous adjuvant therapy
Yes 136 (59%) 134 (58%)
No 94 (41%) 96 (42%)
Primary disease site
Right colon 73 (32%) 61 (27%)
Left colon 67 (29%) 83 (36%)
Rectum 82 (36%) 80 (35%)
Unclear 8 (3%) 6 (3%)
Sites of disease
Liver 175 (76%) 166 (72%)
Lung 115 (50%) 125 (54%)
Mesentery or peritoneal 52 (23%) 47 (20%)
Abdominal lymph nodes 62 (27%) 53 (23%)
Other lymph nodes 31 (13%) 22 (10%)
Bone 13 (6%) 12 (5%)
Other 52 (23%) 54 (24%)
Previous bevacizumab
Yes 4 (2%) 5 (2%)
No 226 (98%) 225 (98%)
Previous oxaliplatin
Yes 219 (95%) 217 (94%)
No 11 (5%) 13 (6%)
Previous best response
Response or stable disease 150 (65%) 148 (64%)
Progressive disease 55 (24%) 60 (26%)
Unknown 25 (11%) 22 (10%)
(Continues in next column)
Irinotecan group 
(n=230)
IrPan group 
(n=230)
(Continued from previous column)
KRASc.12,13,61
Mutant 0 0
Wild-type 230 (100%) 230 (100%)
Undetermined 0 0
BRAFV600E
Mutant 31 (13%) 37 (16%)
Wild-type 188 (82%) 183 (80%)
Undetermined 11 (5%) 10 (4%)
NRASc.12,13,61
Mutant 10 (4%) 19 (8%)
Wild-type 204 (89%) 195 (85%)
Undetermined 16 (7%) 16 (7%)
KRASc.146
Mutant 8 (3%) 9 (4%)
Wild-type 193 (84%) 190 (83%)
Undetermined 29 (13%) 31 (13%)
PIK3CAexon 9/20
Mutant 21 (9%) 11 (5%)
Wild-type 176 (77%) 171 (74%)
Undetermined 33 (14%) 48 (21%)
No mutations detected 163 (71%) 160 (70%)
Any mutation detected 67 (29%) 70 (30%)
Data are n (%) or median (IQR). IrPan=irinotecan plus panitumumab.
Table 1: Baseline characteristics 
For the study protocol see 
http://ctru.leeds.ac.uk/Piccolo
See Online for appendix
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University of Leeds, UK. KRASc.12,13,61 was assessed ﬁ rst; 
KRASc.12,13,61 wild-type tumours were then assessed at 
nine further codons provided suﬃ  cient DNA was 
available: BRAFc.600, NRASc.12,13,61, KRASc.146, PIK3CAc.542,545-6 
(exon 9), and PIK3CAc.1047 (exon 20).
Statistical analysis
Under the original design, we aimed to detect a 25% 
reduction in hazard rate (80% power; 5% signiﬁ cance 
level; two-sided log-rank test) for the primary endpoint, 
overall survival, with the addition of panitumumab to 
irinotecan. Anticipated median overall survival with 
irinotecan was 9 months,11 with a targeted improvement 
to 12 months with the addition of panitumumab, 
resulting in a sample size of 720 patients and at least 
380 deaths. 
In the amended design, we anticipated an increased 
treatment beneﬁ t with IrPan in the reﬁ ned primary 
population of KRASc.12,13,61 wild-type patients not pre-
treated with EGFR monoclonal antibodies. We have 
previously assessed KRAS as a prognostic and predictive 
marker in patients treated with cytotoxic chemotherapy 
alone,10 and on the basis of these data, we made no change 
to the predicted overall survival of 9 months for KRAS 
wild-type patients in the irinotecan alone group. However, 
in the new design we aimed to detect a 30% reduction in 
hazard rate, corresponding to a median overall survival of 
12·9 months with the addition of panitumumab. Target 
accrual was 466 patients in the primary population, with 
the analysis planned after at least 246 deaths had occurred. 
An interim analysis was planned to address inferiority or 
superiority of irinotecan plus panitumumab compared 
with irinotecan alone, with a stringent p value of 0·001, 
therefore no adjustment was required in the ﬁ nal 
signiﬁ cance level.12 Secondary endpoints included 
progression-free survival (PFS), the proportion of patients 
who achieved a RECIST response, quality of life, and 
toxicity. Post-hoc statistical comparisons were made 
between the rates of grade 3 or higher events in the two 
groups, using univariate χ² tests (or Fisher’s exact test for 
ﬁ ve or fewer events) at the 5% signiﬁ cance level. This 
analysis did not account for multiple testing and its 
ﬁ ndings should be interpreted with caution.
We had two predeﬁ ned exploratory populations: 
patients with KRASc.12,13,61-mutated tumours randomised 
to irinotecan versus IrPan before the protocol modiﬁ -
cation; and patients previously treated with an anti-EGFR 
monoclonal antibody.
Additional analyses were later planned, before ﬁ nal 
analysis, to investigate any interaction between 
BRAFc.600, NRASc.12,13,61, KRASc.146, or PIK3CA status and 
the eﬀ ect of panitumumab. In planning these analyses, 
molecular subgroups were predeﬁ ned to determine 
treatment interaction with mutation status, with the 
pre-existing hypothesis that KRASc.12,13,61 wild-type 
patients with a mutation at one of the other loci would 
have less beneﬁ t from panitumumab than would 
patients with no mutations. Patients were grouped as 
having any mutation (a mutation at any other one of the 
assessed loci) or as all wild-type (no mutations at the 
loci tested). In the analysis, missing data for an 
individual gene was imputed as wild-type, but we did a 
sensitivity analysis in which only patients conﬁ rmed to 
be wild-type at all 12 loci were classed as all wild-type. 
We did a second sensitivity analysis excluding PIK3CA 
mutation from the analysis. 
For individual rare mutations occurring in less than 
10% of patients, PICCOLO provides only minimal power 
(about 10%) to detect clinically signiﬁ cant treatment 
eﬀ ects (eg, reduction in hazard rate of 30%). These 
analyses are therefore exploratory in nature and should 
not be over-interpreted. Cox’s proportional hazards 
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Figure 3: Kaplan-Meier curves of (A) overall survival and (B) progression-free survival, at ﬁ nal analysis
IrPan=irinotecan plus panitumumab.
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modelling, adjusting for minimisation factors, was pre-
speciﬁ ed for overall survival and PFS. Statistical testing 
was post hoc for response rate and toxicity. 
Primary analysis of all endpoints was scheduled after 
246 deaths, as per the amended trial design. On 
recommendation from the data monitoring and ethics 
committee, we also planned a ﬁ nal updated analysis of 
overall survival when at least 2 years had passed since 
all patients were allocated to treatment. We report here 
the primary event-driven overall survival analysis in the 
primary population. We also report the secondary 
endpoints and ﬁ nal analysis of overall survival, in the 
primary population, its planned molecular subgroups, 
and in the exploratory population of patients with 
mutations at KRASc.12,13,61. Results in patients previously 
treated with an anti-EGFR monoclonal antibody will be 
reported elsewhere, as will results for the comparison of 
irinotecan versus irinotecan plus ciclosporin. We used 
SAS (version 9.2) for all statistical analyses.
This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN93248876.
Role of the funding source
Cancer Research UK provided independent peer review 
and feedback on the original and revised protocols, but had 
no other involvement in the trial. Amgen Inc provided 
panitumumab and an educational grant, but had no 
involvement in the design, conduct, analysis, inter-
pretation, or production of the report. The corresponding 
author had full access to the data and had full responsibility 
for the decision to submit for publication.
Irinotecan group (n=218*) IrPan group (n=219*) p value†
grade ≥3 
IrPan vs 
irinotecan
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Non-haematological
Nausea 91 (42%) 41 (19%) 13 (6%) 0 0 86 (39%) 40 (18%) 20 (9%) 0 0 0·21
Vomiting 44 (20%) 36 (16%) 15 (7%) 0 0 46 (21%) 32 (15%) 13 (6%) 2 (1%) 0 0·99
Diarrhoea (>24 h post-infusion) 86 (40%) 49 (22%) 38 (17%) 0 1 (<0·5%) 67 (31%) 64 (29%) 59 (27%) 4 (2%) 1 (<0·5%) 0·0053
Diarrhoea (<24 h post-infusion) 17 (8%) 8 (4%) 3 (1%) 0 0 18 (8%) 16 (7%) 1 (<0·5%) 1 (<0·5%) 0 0·69
Constipation 64 (29%) 17 (8%) 0 1 (<0·5%) 0 54 (25%) 23 (11%) 0 0 0 0·50
Abdominal pain 61 (28%) 38 (17%) 12 (6%) 0 0 58 (26%) 23 (11%) 14 (6%) 0 0 0·69
Skin toxicity 47 (22%) 8 (4%) 0 0 0 50 (23%) 103 (47%) 40 (18%) 1 (<0·5%) 0 <0·0001
Nail toxicity 25 (11%) 0 0 ·· ·· 51 (23%) 11 (5%) 5 (2%) ·· ·· 0·061
Alopecia 43 (20%) 141 (65%) ·· ·· ·· 70 (32%) 112 (51%) ·· ·· ·· N/A
Lethargy 78 (36%) 78 (36%) 24 (11%) 0 0 67 (31%) 75 (34%) 43 (20%) 2 (1%) 0 0·0063
Headache 26 (12%) 8 (4%) 0 0 0 24 (11%) 2 (1%) 0 0 0 N/A
Dizziness 36 (17%) 4 (2%) 2 (1%) 0 0 35 (16%) 4 (2%) 2 (1%) 0 0 1·00
Chills or non-neutropenic fever 33 (15%) 3 (1%) 5 (2%) 0 0 38 (17%) 13 (6%) 2 (1%) 2 (1%) 0 0·73
Infection (including febrile neutropenia) 14 (6%) 19 (9%) 19 (9%) 1 (<0·5%) 2 (1%) 7 (3%) 26 (12%) 38 (17%) 4 (2%) 0 0·0072
Any non-haematological 11 (5%) 126 (58%) 76 (35%) 2 (1%) 3 (1%) 4 (2%) 90 (41%) 112 (51%) 12 (5%) 1 (<0·5%) <0·0001
Haematological‡
Neutropenia 19 (9%) 20 (9%) 8 (4%) 17 (8%) 2 (1%) 27 (12%) 15 (7%) 18 (8%) 30 (14%) 0 0·0082
Thrombocytopenia 16 (7%) 1 (<0·5%) 0 0 0 26 (12%) 4 (2%) 4 (2%) 1 (<0·5%) 0 0·06
Anaemia 91 (42%) 27 (12%) 2 (1%) 1 (<0·5%) 0 98 (45%) 22 (10%) 7 (3%) 1 (<0·5%) 0 0·13
Any haematological 82 (38%) 37 (17%) 8 (4%) 18 (8%) 2 (1%) 88 (40%) 23 (11%) 18 (8%) 30 (14%) 0 0·012
Any of the above toxicities 9 (4%) 122 (56%) 64 (29%) 20 (9%) 3 (1%) 4 (2%) 83 (38%) 94 (43%) 37 (17%) 1 (<0·5%)§ <0·0001
Data are n (%), and are for toxicities reported within 12 weeks of randomisation at grade 3 or higher in more than 2% of patients. *The population for adverse event reporting is patients who received at least one 
dose of the allocated treatment, and for whom at least one case record form was received to provide adverse event or serious adverse event data. †Post-hoc univariate χ2 test (Fisher’s exact test when number of 
events is ﬁ ve or fewer) of diﬀ erence in proportion of grade 3–5 events, not adjusting for multiple testing. ‡Nadir blood counts were not obtained routinely. §One treatment-related death (with neutropenic sepsis), 
was reported more than 12 weeks after randomisation. “··” is used where the grading does not exist under NCI CTCAE guidance. 0 is used where the grading does exist but no patients experienced it. 
IrPan=irinotecan plus panitumumab. 
Table 3: Adverse events 
Irinotecan group (n=230) IrPan group (n=230)
Complete response 0 3 (1%)
Partial response 27 (12%) 76 (33%)
Stable disease at 12 weeks 91 (40%) 56 (24%)
Progressive disease at 12 weeks 112 (49%) 95 (41)%)
Radiological progression 69 (30%) 58 (25%)
Clinical progression 10 (4%) 12 (5%)
Death 27 (12%) 20 (9%)
Inadequate data 6 (3%) 5 (2%)
Table 2: Best RECIST response within 12 months of randomisation in the intention-to-treat population
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Results
Starting in December, 2006, 1198 patients were 
recruited to the PICCOLO trial: 494 to the initial three-
arm design (Dec 4, 2006–June 9, 2008), 78 to the 
temporary safety protocol excluding patients with 
mutated or unknown KRAS status from the IrPan 
group (June 10–Aug 31, 2008) and 626 to the fully 
prospectively stratiﬁ ed design (Sept 1, 2008–Aug 31, 
2010). In all, 460 patients with KRAS wild-type tumours 
who had not previously received EGFR therapy were 
randomly allocated to irinotecan (230 patients) or IrPan 
(230 patients), and these form our primary population 
for this report (ﬁ gures 1 and 2; appendix). Baseline 
characteristics were much the same between the two 
groups—most had received oxaliplatin in addition to a 
ﬂ uoropyrimidine and very few had received 
bevacizumab (table 1). Most tumour samples received 
for testing were from patients’ primary tumour; around 
5% were from metastases. 
Patients in both groups received a median of four 
treatment cycles (mean 5·9; range 0–28). 13 (6%) 
patients in the irinotecan group and one (<0·5%) 
patient in the IrPan group received an anti-EGFR 
Total (n) Irinotecan
(n)
Hazard ratio (95% CI) for 
overall survival 
comparison vs wild-type 
in irinotecan group
All wild-type 323 163 NA
Any mutation 137 67 1·36 (1·00–1·83); p=0·049
BRAF mutation 68 31 1·56 (1·03–2·37); p=0·035
NRAS mutation 29 10 1·15 (0·60–2·21); p=0·67
KRASc.146 mutation 17 8 1·77 (0·85–3·69); p=0·13
PIK3CA mutation 32 21 1·11 (0·68–1·80); p=0·69
A hazard ratio greater than one indicates worse survival for patients in mutation 
group compared with all wild-type patients. 
Table 4:  Prognostic analysis 
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Figure 4: Key eﬃ  cacy endpoints, by mutation status
(A) Overall survival in patients with no mutations. (B) Progression-free survival in patients with no mutations. (C) Overall survival in patients with any mutation. (D) Progression-free survival in 
patients with any mutation. IrPan=irinotecan plus panitumumab.
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monoclonal antibody as salvage therapy within 3 months 
of ﬁ nishing trial treatment.
The primary analysis of overall survival was triggered 
after 246 deaths, although when the database was locked 
for analysis, 312 (68%) of 460 patients had died. The 
analysis was presented in full at an international 
conference in 2011:13 in brief, median overall survival was 
10·5 months (95% CI 9·5–12·4) in the irinotecan group 
and 10·4 months (8·7–12·2) in the IrPan group (hazard 
ratio [HR] 0·91, 95% CI 0·73–1·14; p=0·44). Thus, 
PICCOLO did not meet its primary objective of showing 
improved overall survival in the primary analysis 
population. 
All further overall survival analyses presented in this 
report use ﬁ nal survival data. At ﬁ nal analysis, 419 (91%) 
of 460 patients in the primary population had died, and 
median follow-up of those patients still alive (n=41) was 
25·4 months (IQR 22·5–30·8). At ﬁ nal analysis, we 
recorded no diﬀ erence in overall survival between the 
groups: median survival was 10·9 months (95% CI 
9·5–12·5) in the irinotecan group and 10·4 months 
(8·9–12·2) in the IrPan group (HR 1·01, 95% CI 
0·83–1·23; p=0·91;  ﬁ gure 3). 
Secondary endpoints were analysed after data cleaning 
at the time of the primary event-driven overall survival 
analysis. PFS was longer in the IrPan group than in the 
irinotecan group (HR 0·78, 95% CI 0·64–0·95; p=0·015; 
ﬁ gure 3). More patients had a RECIST-deﬁ ned response 
in the IrPan group than in the irinotecan group (table 2), 
with a multivariate odds ratio of 4·12 (95% CI 2·52–6·76; 
p<0·0001). 
Adverse events are summarised in table 3. Brieﬂ y, the 
toxicity of the two regimens was consistent with 
summaries of product characteristics for irinotecan and 
panitumumab, and in line with previous trials of anti-
EGFR monoclonal antibodies. In terms of events that 
were grade 3 or higher, diarrhoea, lethargy, skin toxicity, 
infection, and neutropenia were all more common in the 
IrPan group than in the irinotecan group, as were any 
haematological, any non-haematological, or a grade 3 or 
higher toxicity of any type. However, there was no 
increase in the number of deaths attributed wholly or 
partly to treatment (three patients with irinotecan, two 
patients with IrPan), or in 60-day all-cause mortality 
(12 patients with irinotecan, 14 patients with IrPan).
13 patients did not receive any trial treatment (seven 
allocated to irinotecan, six to IrPan). Of those who did, 
66 (30%) of 223 patients on irinotecan and 89 (40%) of 224 
patients on IrPan needed an irinotecan dose modiﬁ cation 
during cycles 1–4; panitumumab dose modiﬁ cations were 
required for 60 (27%) of 224 patients during cycles 1–4. 
Of patients who were alive and completed quality-of-
life questionnaires at 24 weeks post-randomisation 
(111 [70%] of 158 patients in the irinotecan group, 
125 [75%] of 167 patients in the IrPan group), EORTC 
QLQ-C30 global quality-of-life scores at 24 weeks, after 
adjusting for baseline quality of life, were moderately 
better14 with IrPan than with irinotecan alone (mean 56·4 
vs 49·5; diﬀ erence 7·0, 0·6–13·4, two-sided p=0·032). By 
contrast with the global scores, and in keeping with the 
clinician-reported adverse events (table 3), quality-of-life 
symptom scores were worse with IrPan (data not shown).
Of the 460 patients in the primary population, 137 (30%) 
were classiﬁ ed as having any mutation and 323 (70%) 
were all wild type (table 1 and ﬁ gure 2). Mutations 
aﬀ ecting more than one gene were uncommon (ﬁ gure 2). 
Mutation status was ﬁ rst assessed as a prognostic 
variable for overall survival in patients treated with 
irinotecan alone (table 4). When corrected for prognostic 
variables (minimisation factors), patients in the any 
mutation group had inferior survival to all wild-type 
patients (p=0·049). Patients with BRAF-mutated 
tumours had worse overall survival than did all-wild-type 
patients (table 4). However, the numbers of patients in 
these subgroup analyses is small and these exploratory 
results should be interpreted with caution.
We then assessed mutation status as a predictive 
biomarker of the eﬀ ect of panitumumab treatment on 
HR (95% CI)Deaths/total
1·01 (0·83–1·23) 419/460
Interaction p value
0·92 (0·73–1·16)286/323All-wt
1·64 (1·14–2·34) 133/137 0·028Any-mut
1·84 (1·10–3·08)   66/68 0·029BRAF-mut
1·97 (0·83–4·67)   29/29 0·23NRAS-mut
1·73 (0·45–6·58)    17/17 0·76KRASc.146-mut
1·11 (0·50–2·47)   30/32 0·97PIK3CA-mut
1·05 (0·69–1·61) 101/103KRASc.12,13,61-mut*
0·1 0·2 0·5 1·0 2·0 5·0 10·0
0·68 (0·53–0·86) 276/323All-wt
Total
Total
1·20 (0·83–1·74)123/137 0·018Any-mut
1·40 (0·82–2·39)  63/68BRAF-mut
1·08 (0·45–2·56)   25/29NRAS-mut
0·56 (0·13–2·48)   15/17KRASc.146-mut
1·39 (0·60–3·23)   28/32PIK3CA-mut
1·20 (0·79–1·83)102/103KRASc.12,13,61-mut*
Favours IrPan Favours irinotecan
0·78 (0·64–0·95)399/460
A
··
··
··
···
··
··
··
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··
B
Figure 5: Subgroup analysis, by mutation status 
Forest plot of (A) overall survival and (B) progression-free survival. Hazard ratios (HRs) and 95% CIs are corrected 
for minimisation factors, comparing irinotecan plus panitumumab (IrPan) vs irinotecan alone. All-wt=no 
mutations detected. Any-mut=any mutation detected. *Patients randomised before the protocol amendment in 
June 10, 2008, and genotyped retrospectively.
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overall survival, PFS, and response rate, using tests of 
interaction with mutation status (any mutation vs all wild-
type), corrected for prognostic variables. The interaction 
tests assess whether there is a true diﬀ erence between the 
two subpopulation in the impact of adding panitumumab 
to irinotecan. The interaction test was positive for all three 
outcome measures: overall survival (p=0·028, 
ﬁ gures 4 and 5A), progression-free survival (p=0·018, 
ﬁ gure 5B) and response rate (p=0·0095, appendix). In 
patients with all-wild-type tumours, those in the IrPan 
group had better PFS and response rate than did those in 
the irinotecan groups (ﬁ gures 4B and 5B, appendix), but 
we detected no between-group diﬀ erence in terms of 
overall survival (ﬁ gure 5). By contrast with this ﬁ nding, in 
patients with any mutation, panitumumab had no eﬀ ect 
on PFS or response rate (ﬁ gure 5B, and appendix) and an 
adverse eﬀ ect on overall survival (ﬁ gures 4C and 5A). For 
individual mutations, the small numbers provide 
insuﬃ  cient power to conﬁ dently detect or refute 
interactions between treatment eﬀ ect and mutation status, 
so results are exploratory. For patients with BRAF-mutated 
tumours, there was a suggestion of harm with 
panitumumab (ﬁ gure 5A). The eﬀ ect of panitumumab on 
PFS and response rate in the individual mutation 
subgroups gave less consistent results than for overall 
survival (ﬁ gure 5B, appendix). A breakdown of PFS events 
(by all wild-type vs any mutation) is shown in the appendix. 
A sensitivity analysis including only patients with a full 
set of data in the all-wild-type group gave similar HRs 
and eﬀ ect sizes to those for the whole all-wild-type 
population for all endpoints (appendix). Similarly a 
sensitivity analysis excluding individuals with PIK3CA 
mutations did not alter the ﬁ ndings (appendix). Separate 
analysis of PIK3CA exon 9 and 20 is of minimal relevance 
given the small numbers in these groups (appendix). 
In view of the disparity between treatment eﬀ ects on 
overall survival and PFS, we did a post-hoc analysis of 
survival after progression. Post-progression survival was 
reduced in patients in the IrPan group, and this 
diﬀ erence was more pronounced in the any-mutation 
population (appendix). 
494 patients were enrolled and randomly allocated before 
the protocol modiﬁ cation, 329 to irinotecan or irinotecan 
plus panitumumab. Of these, 261 had tumour samples 
available for retrospective analysis (132 in the irinotecan 
group and 129 in the IrPan group). 103 (39%; 53 in the 
irinotecan group, 50 in the IrPan) had a KRASc.12,13,61 
mutation (including 17 patients with Gly13Asp mutations; 
ten in the irinotecan group, seven in the IrPan group). We 
detected no treatment eﬀ ect (beneﬁ cial or detrimental) 
with panitumumab in these individuals (ﬁ gure 5 and 
appendix). We detected no beneﬁ t of panitumumab in the 
Gly13Asp mutation subgroup (data not shown).
Discussion 
In our trial, the addition of panitumumab to irinotecan 
for patients with KRAS wild-type tumours had no eﬀ ect 
on overall survival, which was our primary endpoint. 
However, the addition of panitumumab improved the 
secondary outcome measures of PFS and the proportion 
of patients who had a response. Our ﬁ ndings are in 
keeping with the emerging pattern of clinical eﬀ ect of 
anti-EGFR monoclonal antibody therapy in patients with 
KRAS wild-type colorectal cancer (panel).
To the best of our knowledge, PICCOLO is the ﬁ rst 
randomised trial in advanced colorectal cancer to have 
introduced prospective testing of mutation status to 
determine patients’ randomisation and treatment. It 
shows that rapid testing by a central laboratory is feasible 
in a multi-centre research setting. In addition to prospective 
stratiﬁ cation by KRASc.12,13,61 status, PICCOLO included a 
prospectively planned, retrospective analysis of other 
candidate mutations in the MEK/AKT activation pathway. 
Determination of the eﬀ ect of less common mutations is 
challenging, because any randomised trial powered for a 
common group (eg, KRAS wild-type) is inevitably 
underpowered to detect or exclude potentially clinically 
important eﬀ ects in rarer subgroups (eg, BRAF mutation). 
In PICCOLO, we grouped several candidate mutations in 
the EGFR signalling pathway, allowing a higher-powered 
comparison of any mutation versus all-wild-type than 
would be possible for individual mutations. This approach 
Panel: Research in context
Systematic review
We searched Medline using OvidSP for published randomised clinical trials in advanced 
colorectal cancer involving an anti-EGFR monoclonal antibody. We used the following 
searchterms: “colorectal”, “randomis[z]ed”, “panitumumab”, “cetuximab”. Our last search 
was done on Jan 22, 2013, and we used no language restrictions. We identiﬁ ed 12 trials 
that included randomisation to standard treatment plus or minus anti-EGFR monoclonal 
antibodies.1–3,17,18,23–29 In none was KRAS status determined before randomisation, but for ten 
trials results have been published by KRAS status (usually conﬁ ned to codons 12–13) either 
within the primary analysis or as a secondary report. Two useful meta-analyses of these ten 
trials have been done, drawing attention to a lack of consistency in outcomes, especially 
among patients with KRAS wild-type tumours.16,30 Unexplained antagonistic interactions 
with other cancer drugs have been proposed: combinations with bevacizumab, 
capecitabine, or oxaliplatin have produced poor results, whereas single-agent therapy or 
combinations with irinotecan or ﬂ uorouracil have had more success. Another trend, also 
unexplained, is toward worsening outcomes with earlier stage disease: clear beneﬁ t in the 
third-line setting, lesser beneﬁ t in second line, mixed results in ﬁ rst-line, and negative 
results in two large surgical adjuvant trials.31,32
Interpretation
Our ﬁ ndings for KRASc.12,13,61 wild-type patients show that prospective molecular 
stratiﬁ cation is feasible and gives outcomes consistent with these previous retrospective 
analyses. As in the two previous second-line studies of panitumumab,24,25 we saw 
improved response rate and progression-free survival, but with no eﬀ ect on overall 
survival. However, ﬁ ndings from other trials of alternative novel agents should also be 
considered. For example, randomised trials have shown small, but statistically signiﬁ cant, 
improvements in survival when either bevacizumab33 or aﬂ ibercept34 is added to 
chemotherapy in the second-line setting. Thus, only if further reﬁ nement of molecular 
selection resulted in a substantial survival beneﬁ t from therapeutic antibodies targeting 
EGFR would they become the preferred option in this clinical setting.
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does not mean that every mutation selected is individually 
important, nor that the list is exhaustive; it does, however, 
provide evidence that interactions exist. The choice of 
mutations was based on their roles as oncogenes in EGFR 
signal transduction, coupled with data from grouped 
retrospective analyses of non-randomised patients 
suggesting clinical relevance.15,16 Least certain is the 
relevance of PIK3CA, where non-randomised data has 
implicated exon 20, but not exon 9, as a negative 
biomarker.15 The small number of patients with mutations 
at PIK3CA in PICCOLO precludes ﬁ rm conclusions; 
however, patients with mutations at exon 9 did not beneﬁ t 
from panitumumab, and the sensitivity analysis excluding 
PIK3CA from the list did not alter that ﬁ nding (appendix).
An inconsistent, but nonetheless worrying, ﬁ nding in 
trials of anti-EGFR monoclonal antibodies is that patients 
who do not beneﬁ t from treatment are potentially harmed. 
Findings of a meta-analysis including ten randomised 
controlled trials in advanced colorectal cancer showed, 
although not statistically signiﬁ cant, a trend towards 
worse PFS in patients with KRAS mutations (HR 1·11, 
95% CI 0·97–1·27);17 three of the ten trials showed a 
statistically signiﬁ cant detrimental eﬀ ect.3,18,19 Drug-
speciﬁ c adverse interactions with oxaliplatin and 
bevacizumab have been inferred, although on no basis 
and with no mechanism proposed, and this has led to a 
supposition that anti-EGFR monoclonal antibodies are 
better paired with irinotecan than with other drugs.16 
We have now shown in this prospective randomised 
trial, including irinotecan, but neither oxaliplatin nor 
bevacizumab, that the KRAS wild-type population 
contains subpopulations for whom anti-EGFR monoclonal 
antibodies are similarly detrimental. The all wild-type 
population of patients beneﬁ ted from panitumumab, with 
a high response rate (70 [44%] of 160 patients) and 
improved PFS (HR 0·68; 95% CI 0·53–0·86); but we saw 
no statistically signiﬁ cant diﬀ erence in overall survival 
between the two groups (ﬁ gures 4 and 5). By contrast with 
these ﬁ ndings, in patients with any mutation, we detected 
a potential detrimental eﬀ ect of panitumumab in terms of 
PFS and of overall survival (ﬁ gures 4 and 5).
This disparity between eﬀ ects on PFS and overall 
survival is substantiated by our ﬁ ndings that suggested 
shorter survival after progression following irinotecan 
and panitumumab, especially in the any-mutation 
population (appendix). Several possible explanations 
must be considered. Imbalanced post-trial treatment 
with more eﬀ ective salvage of patients in the control 
group is unlikely to have been a major factor: the use of 
anti-EGFR monoclonal antibodies was carefully 
monitored, but these drugs were not funded in the UK at 
the time of the trial and were received by only 13 (6%) 
patients in the control group in the 3 months after 
progression. Although the fact that full data were not 
collected for other salvage treatments is a weakness of 
this study, there is no reason to believe that these would 
have been imbalanced. Ascertainment bias—a lower 
threshold for diagnosing progression in patients in the 
control group—is also unlikely, because there was a 
higher rate of conﬁ rmed radiological progression in the 
control group than in the experimental group (appendix). 
The third explanation is that panitumumab caused 
accelerated tumour growth during or after therapy. This 
seems to have been the case in the population of patients 
with any mutations, in which the progression event was 
death for a higher proportion, and where substantially 
inferior survival after progression suggests more rapid 
tumour growth after stopping treatment (appendix).
The demonstration of detriment within subpopulations 
of KRAS wild-type patients casts doubt on the current 
select-out approach to anti-EGFR monoclonal antibody 
therapy, in which the default position is to treat unless 
the patient is in a group of well-proven ineﬃ  cacy (eg, 
with a mutation at KRASc.12,13). Urgent clariﬁ cation of 
subpopulations at risk of harm is important, but positive 
biomarkers are also needed, to allow a change to a select-
in strategy, using anti-EGFR monoclonal antibodies in 
only well-deﬁ ned molecular groups with proven eﬃ  cacy. 
Potential, although not validated, positive biomarkers 
include EGFR ligands20 and EGFR copy number.21,22
For the individual mutations tested in PICCOLO, the 
numbers of patients were insuﬃ  cient to provide clear 
results. The exception was in patients with mutations in 
BRAF, the most common mutation, in whom we 
detected a detrimental eﬀ ect of panitumumab on overall 
survival (HR 1·84, 95% CI 1·10–3·08). Findings from 
previous studies of patients with BRAF mutations are 
inconsistent. Large, but non-randomised, series suggest 
that anti-EGFR monoclonal antibodies are inactive in 
BRAF-mutated cancers;14,15,17 however, retrospective 
analysis of BRAF status in two randomised trials, 
although showing a low response rate in patients with 
BRAF mutations, showed no evidence of a negative 
interaction on PFS.2
The data presented here substantiate the activity of 
anti-EGFR monoclonal antibodies in advanced colorectal 
cancer, but also show the need for selection strategies 
beyond the current reliance on KRAS. Rapid independent 
validation or refutation of the PICCOLO ﬁ ndings is 
feasible using existing clinical trial biobanks. Urgent 
reﬁ nement of both negative and positive selection 
biomarkers using preclinical studies and both 
retrospective and prospective clinical trial analysis are 
needed if best use is to be made of an eﬀ ective targeted 
therapy for the beneﬁ t of patients.
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